Abstract | BACKGROUND: METHODS: We identified all patients with HER2-positive MBC who received T-DM1 between April 1, 2014 and February 28, 2017 in our institution. The patients were divided into the Tmab group (i.e., those who received only Tmab before T-DM1 treatment) and the Tmab/Pmab group (i.e., those who received Tmab and Pmab before T-DM1 treatment), and progression-free survival (PFS) and best response were compared between the two groups. RESULTS: A total of 42 patients were enrolled for outcome analysis. The median follow-up period was 4.8 months, and the median number of prior chemotherapy regimens for metastatic disease before T-DM1 was 1 (range 1-2) in the Tmab/Pmab group and 2 (range 0-6) in the Tmab group. The median PFS was 2.8 months in the Tmab/Pmab group (95% confidence interval [CI] 1.7-4.8 months) and 7.8 months in the Tmab group (95% CI 5.5-15.9 months) (p = 0.0030). The best response was lower in the Tmab/Pmab group (11.1% vs. 25.0%). CONCLUSIONS: Patients with HER2-positive MBC who received Tmab and Pmab treatment before T-DM1 have fewer benefits from T-DM1.
|
Authors | Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, Hitomi Sumiyoshi-Okuma, Kazuki Sudo, Tatsunori Shimoi, Emi Noguchi, Kan Yonemori, Chikako Shimizu, Yasuhiro Fujiwara, Kenji Tamura |
Journal | Breast cancer (Tokyo, Japan)
(Breast Cancer)
Vol. 26
Issue 4
Pg. 492-498
(Jul 2019)
ISSN: 1880-4233 [Electronic] Japan |
PMID | 30737616
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Maytansine
- ERBB2 protein, human
- Receptor, ErbB-2
- pertuzumab
- Trastuzumab
- Ado-Trastuzumab Emtansine
|
Topics |
- Ado-Trastuzumab Emtansine
(administration & dosage)
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Asian People
- Breast Neoplasms
(drug therapy, mortality, pathology)
- Female
- Humans
- Kaplan-Meier Estimate
- Maytansine
(administration & dosage)
- Middle Aged
- Receptor, ErbB-2
(metabolism)
- Retrospective Studies
- Trastuzumab
(administration & dosage, therapeutic use)
- Treatment Outcome
|